JDRF Teams Up with Pfizer's Centers for Therapeutic Innovation to Support Novel Translational Research in Type 1 Diabetes

  JDRF Teams Up with Pfizer's Centers for Therapeutic Innovation to Support
               Novel Translational Research in Type 1 Diabetes

PR Newswire

NEW YORK, Nov. 4, 2013

NEW YORK, Nov. 4, 2013 /PRNewswire-USNewswire/ -- JDRF, the leading global
organization funding type 1 diabetes (T1D) research, announced today a
partnership with Pfizer's Centers for Therapeutic Innovation (CTI) to support
the development and translation of promising diabetes research. The
collaboration, announced during the Partnering for Cures Conference in New
York, will initially focus on co-funding projects in the fields of immune
tolerance, diabetic nephropathy, and beta cell health. Capitalizing on JDRF's
expertise in the field of T1D research and CTI's network of academic medical
centers, the organizations will work together to identify and drive promising
research projects.

"This is a very exciting partnership for JDRF with tremendous opportunities to
work with Pfizer's Centers for Therapeutic Innovation to advance progress
toward new treatments and therapies for people with type 1 diabetes," says
Jeffrey Brewer, president and CEO of JDRF. "JDRF is dedicated to delivering
tangible improvements in the treatment of type 1 diabetes that may improve
outcomes for people with the disease until there is a cure and it no longer
exists. By harnessing resources and expertise from both of our organizations,
we can speed the development and delivery of better treatments that could
improve millions of lives – a vision shared by JDRF and CTI."

CTI is a pioneering open-innovation partnering model designed by Pfizer,
wherein Pfizer employees work side by side with leading scientific
investigators and post-docs from academic medical centers to accelerate drug
discovery and development. The partnership between JDRF and CTI exemplifies a
results-driven model of collaboration that is enriching the landscape of
research and development, where leading players from the non-profit world,
industry, and academia work together to achieve tangible progress for
patients. Under the terms of the collaboration, JDRF and Pfizer will co-fund
up to four jointly-selected projects.

"CTI's business model is to build novel partnerships that combine our drug
discovery expertise with external innovation, and we've found a great partner
in JDRF,"says Dr. Anthony J. Coyle, chief scientific offer at Pfizer's CTI.
"Combining Pfizer's scientific resources with JDRF's deep knowledge of type 1
diabetes and excellent network of investigators, I believe we will be
well-positioned to pursue better, more targeted medicines for diabetes
patients."

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D)
research. JDRF's goal is to progressively remove the impact of T1D from
people's lives until we achieve a world without T1D. JDRF collaborates with a
wide spectrum of partners and is the only organization with the scientific
resources, regulatory influence, and a working plan to better treat, prevent,
and eventually cure T1D.

As the largest charitable supporter of T1D research, JDRF is currently
sponsoring $530 million in scientific research in 17 countries. In 2012 alone,
JDRF provided more than $110 million to T1D research. More than 80 percent of
JDRF's expenditures directly support research and research-related education.
In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing
the organization's efficiency and effectiveness.

For more information, please visitjdrf.org.

SOURCE JDRF

Website: http://www.jdf.org